US Biosimilars ‘Bumpy’ For Teva As It Prepares For Alvotech Inspection

CEO Hints At More Deals On The Horizon Despite A Degree Of Market Uncertainty

 
• By David Wallace
  
Road sign warning of bumps ahead
Teva’s CEO sees the US market as “bumpy” • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business